XU HANMEI has a total of 27 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2006. It filed its patents most often in Republic of Korea, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are THERAVAC PHARMACEUTICALS AB, NETWORK IMMUNOLOGY INC and MILHAUD GERARD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 5 | |
#2 | United States | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Australia | 3 | |
#6 | China | 3 | |
#7 | India | 1 | |
#8 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Xu Hanmei | 26 |
#2 | Kang Zhian | 14 |
#3 | Pu Chunyan | 12 |
#4 | Chang Haimin | 7 |
#5 | Shen Hong | 5 |
#6 | Xu Hanmei Kang | 1 |
#7 | Hu Jialiang | 1 |
#8 | Yang Yongjing | 1 |
Publication | Filing date | Title |
---|---|---|
CN108623692A | A kind of fusion protein and preparation method thereof and its application | |
CN108623693A | A kind of fusion protein and preparation method thereof and its preparing treatment ophthalmology disease, anti-inflammatory, in antitumor drug application | |
US2017051018A1 | Integrin-blocking polypeptides and uses thereof | |
CN1830487A | Blood vessel formation inhibitor IIM3 and its preparation method and application |